Company news
Stoke Therapeutics, Inc. (NASDAQ:STOK) news
Every Stoke Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the T...
September 1, 2026
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
July 27, 2026
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
July 13, 2026
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational ...
June 30, 2026
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
April 30, 2026
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
April 14, 2026
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
April 7, 2026
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
March 4, 2026
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of...
February 12, 2026
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of...
February 11, 2026
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
January 27, 2026
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
January 19, 2026
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 16, 2026
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Z...
January 11, 2026
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medic...
December 5, 2025
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medic...
December 5, 2025
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 1, 2025
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Includ...
November 17, 2025
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Includ...
November 17, 2025
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
November 5, 2025
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 4, 2025
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
October 30, 2025
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
October 20, 2025
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zor...
October 9, 2025
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zor...
October 9, 2025
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
October 6, 2025
MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board
September 15, 2025
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be ...
September 2, 2025
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be ...
September 2, 2025
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025
August 28, 2025
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet ...
August 25, 2025
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet ...
August 25, 2025
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatm...
August 11, 2025
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
August 7, 2025
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
August 6, 2025
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2025
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome...
July 10, 2025
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome...
July 10, 2025
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2025
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
May 13, 2025
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
Stoke Therapeutics Announces CEO Transition
March 18, 2025
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 18, 2025